Landmark Clinical Trials: The Foundation
Modern psilocybin research resumed in earnest in the 2000s after decades of restriction. The foundational studies that opened the current era include:
- Griffiths et al. (2006), Johns Hopkins: A landmark randomised controlled trial demonstrating that high-dose psilocybin produced mystical-type experiences with lasting positive effects on well-being in healthy volunteers. Published in Psychopharmacology.
- Carhart-Harris et al. (2016), Imperial College London: Open-label feasibility study of psilocybin for treatment-resistant depression (TRD), showing significant reductions in depressive symptoms at 1-week and 3-month follow-ups. Lancet Psychiatry.
- Ross et al. (2016), NYU: Randomised crossover trial showing single-dose psilocybin produced rapid and sustained reductions in cancer-related existential distress. Journal of Psychopharmacology.
- Davis et al. (2021), Johns Hopkins: Randomised controlled trial showing psilocybin-assisted therapy produced large, rapid reductions in major depressive disorder (MDD) symptoms, with effects maintained at 4-week follow-up. JAMA Psychiatry.
- COMPASS Pathways Phase 2b trial (2022): The largest randomised controlled trial of psilocybin (COMP360) for TRD to date, with 233 participants across multiple sites in Europe and North America. Published in New England Journal of Medicine. Found statistically significant antidepressant effects at the 25mg dose at 3 weeks, with a substantial minority achieving remission.
Active Research Areas in 2024–2025
Treatment-Resistant Depression (TRD)
COMPASS Pathways is now conducting a Phase 3 trial (COMP360) for TRD across multiple countries including UK sites. The phase 3 programme represents the most advanced commercial clinical programme in psychedelic medicine globally. Results are expected in the 2026–2027 timeframe and may inform regulatory applications to the FDA and MHRA.
Major Depressive Disorder (MDD)
The Imperial College London Centre for Psychedelic Research and Johns Hopkins Centre for Psychedelic and Consciousness Research continue to run trials examining psilocybin for MDD with and without psychotherapy. Research is exploring optimal dosing schedules, the therapeutic contribution of set and setting, and whether outcomes differ with and without supportive therapy.
Alcohol Use Disorder
A randomised controlled trial from NYU Langone (Bogenschutz et al., 2022, published in JAMA Psychiatry) showed psilocybin-assisted therapy led to significantly greater reductions in heavy drinking days versus placebo, with effects sustained at 8-month follow-up. Follow-on trials are underway at multiple institutions.
Tobacco / Smoking Cessation
Johns Hopkins has published promising open-label pilot data on psilocybin-assisted smoking cessation (Johnson et al., 2014), with 80% abstinence at 6 months in a small cohort. A larger randomised controlled trial is underway, with results anticipated in 2025–2026.
OCD and Eating Disorders
Early-phase trials for obsessive-compulsive disorder (OCD) and anorexia nervosa are underway at several institutions. These represent newer therapeutic targets with less established evidence than depression; results should be treated as preliminary.
Microdosing Research
Controlled studies on microdosing (sub-perceptual doses, typically 0.1–0.3g) have produced more ambiguous results than the headline studies on full-dose therapy. A randomised controlled trial by Szigeti et al. (2021, eLife) using a self-blinding methodology found that open-label expectation accounted for a significant portion of reported benefits, though neurobiological effects were also observed. The field continues to investigate dose-response relationships.
Neuroscience: How Psilocybin Affects the Brain
Brain imaging research (fMRI, MEG, EEG) conducted primarily at Imperial College London has contributed important mechanistic understanding:
- Default Mode Network (DMN) suppression: Psilocybin reduces activity and connectivity in the DMN — a network associated with self-referential thinking, rumination, and the "ego." This suppression correlates with the subjective experience of ego dissolution and may underlie antidepressant effects.
- Increased global brain connectivity: Psilocybin induces a state of "brain entropy" — more random and diverse patterns of neural communication — which may facilitate psychological flexibility and openness to new perspectives.
- 5-HT2A agonism: Psilocin (the active metabolite of psilocybin) acts primarily as a partial agonist at serotonin 5-HT2A receptors. This mechanism is distinct from SSRIs, which block serotonin reuptake; the two mechanisms have different (and potentially interacting) effects, which is why SSRIs may blunt the effects of psilocybin.
- Neuroplasticity: Animal and in vitro studies suggest psilocybin may promote dendritic spine growth and synaptic plasticity — a possible neurobiological basis for lasting therapeutic change. Human studies are investigating this hypothesis.
Regulatory Milestones
- FDA Breakthrough Therapy designation: Granted to psilocybin for TRD (COMPASS Pathways, 2018) and MDD (Usona Institute, 2019). This designation accelerates the review process but is not a drug approval.
- Australian TGA rescheduling (2023): First national regulatory body to permit authorised psychiatrist prescription of psilocybin for TRD.
- UK MHRA ILAP designation: Granted to COMP360, signalling regulatory intent to engage with psilocybin through an accelerated access pathway.
How to Find and Read the Primary Research
- ClinicalTrials.gov: Search "psilocybin" to find all registered trials, their status, locations, and eligibility criteria.
- PubMed (pubmed.ncbi.nlm.nih.gov): Search for peer-reviewed publications. Many are open access; look for PubMed Central (PMC) links.
- Psychedelic Alpha (psychedelicalpha.com): Tracks clinical programmes and regulatory developments with primary sourcing.
- Imperial College London Centre for Psychedelic Research: Publishes updates on their active programmes and open-access papers.